May 27, 2019tgn 1412

Infrastructure Worries

DIA: Parexel CEO On India

June 21, 2007

Ten years after it launched its first office in Japan, contract research organization (CRO) Parexel announced a new office in Hyderabad, India. A city of 8 million in the heart of the subcontinent, Hyderabad is the sixth largest in India and a leading center for IT and biotechnology. “Our foray into India, we started four or five years ago,” says Josef von Rickenbach, the company’s chairman and CEO. He met a few trade journalists at the 2007 annual meeting of the Drug Information Association (DIA). During the meeting, the Waltham, Mass. company celebrated its 25th anniversary. A co-founder, von Rickenbach noted that the company had expanded its ownership of a joint venture with India’s Synchron. That entity does Phase II-III studies in India. India’s recent efforts to make itself more attractive to industry were one factor in the U.S. company’s decision, von Rickenbach said. “The regulatory environment was not conducive to…more...

Will Parexel Settle?

TeGenero Litigation

March 19, 2007

The British trade publication Pharma Times describes the strategy of London lawyers representing the six patients in an ill-fated Phase I trial sponsored by TeGenero. That German sponsor had only $3.9…more...

Patient Grants Interview

BBC Rehashes TeGenero Trial

December 08, 2006

Most ClinPage readers are familiar with the ill-fated TeGenero trial of TGN1412, a Phase I study that went awry earlier this year. The BBC is revisiting the matter. The most debilitated…more...

No articles available

No articles available

© 2019 ClinPage. All Rights Reserved.